{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.7","upperLimit":"75","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"PFS was defined as the time from registration to progression or death due to any cause. The median PFS with 95%CI was estimated using the Kaplan Meier method.\n\nProgression was defined as any one or more of the following:An increase of 25% from lowest confirmed response in:\n\n* Serum M-component (absolute increase \\>= 0.5g/dl)\n* Urine M-component (absolute increase \\>= 200mg/24hour\n* Difference between involved and uninvolved Free Light Chain levels (absolute increase \\>= 10mg/dl\n* Bone marrow plasma cell percentage (absolute increase of \\>=10%)","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.\n\nDexamethasone: 10-40 mg once weekly (days 1, 8, 15, \\& 22) orally with food until progression.","id":"OG000","title":"Lenalidomide With On-Demand Dexamethasone"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from registration to progression or death (up to 3 years)","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}